Ocular therapeutics company Novaliq names new CEO

Novaliq GmbH said yesterday that it named Christian Roesky as its new CEO, replacing co-founder Bernhard Günther, who will take on a new role as chief innovation officer.

The Heidelberg, Germany-based company focuses on renovating poorly soluble drugs into effective ocular therapeutics. Its CE-marked product, NovaTears, was developed from its proprietary EyeSol technology. With its reshuffled executive team, Novaliq said it hopes to continue developing therapeutics for ophthalmic indications such as dry eye, glaucoma and retina diseases.

Get the full story at our sister site, Drug Delivery Business News.

The post Ocular therapeutics company Novaliq names new CEO appeared first on MassDevice.

from MassDevice http://ift.tt/2dEZ2Go